Option chain shows key data for Powerstorm Hldgs's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Powerstorm Hldgs.

Powerstorm Hldgs (OTC:PSTO) Stock, Option Chain

Powerstorm Holdings Inc is a consortium of privately held sustainability-focused companies acquired for scalable growth, streamlined into three categories: Telecom, Power, and Real Estate Investment (REI).

News

Intraday Update

Markets

Movers

Trading Ideas

ACHN

ADSW

AHPI

ARXRF

ASNB

BCOW

BTBIF

CBCFF

CBLI

CGEN

CSBTF

CTLT

DEAC

DLT RESOLUTION INC by DLT Resolution Inc.

DLTI

EVRG

FCPT

FTMNF

GCFFF

GJNSY

GLGDF

GVDNY

HBAYF

HTCMF

LAKE

LAND

LGDOF

LGDTF

LLIT

LYTS

Blackrock Muniholdings Investment Quality Fund

Blackrock Muniholdings New York Quality Fund

MITEY

Blackrock Muniyield Michigan Quality Fund

MMIRF

Blackrock Muniyield Pennsylvania Quality Fund

MRNTF

Blackrock Muniholdings California Quality Fund

Blackrock Muniyield New York Quality Fund

Nuveen Insured Tax-Free Advantage Municipal Fund

Nuveen Insured New York Tax-Free Advantage Municipal Fund

NVRO

Nuveen New Jersey Dividend Advantage Municipal Fund

OCPNY

OPYGY

PCYO

PLHCF

POYYF

QIFTF

QMCO

QTRHF

RWNFF

SNPHF

SPFI

TGLVY

TPRFF

VCNX

WFCF

WOSSF

XPPLF

MZEIQ

ALTKF

PHYS

NNVC

PSTO

FPWM

Stocks That Hit 52-Week Highs On Monday

ALVVF

APPS

APRO

ATEC

AURI

AVXT

BBBXF

BLHEY

BMCH

CBOE

CETV

CHPGF

CINF

CLSI

CMXC

CNMD

COLD

CONC

CUBE

CVNA

CYRX

DPMLF

FERN

GMAB

GNMSF

GOLD

GRWG

HLND

IMOS

ITMC

MIRM

MISVF

MXSG

NSRGF

Nestle Sponsored representing Registered Shares Series B

NSRGY

Nuveen Insured Dividend Advantage Municipal Fund

Nuveen Dividend Advantage Municipal Fund 3

ORZCF

PERI

PFGC

PMSNF

PODD

PRNB

RGLD

RNSGF

ROGFF

ROKU

SEDG

SLVRF

SWCH

TCEGF

TMCX

TNAV

TORXF

TRXD

WELL

WKLDF

CSPCY

TRZBF

SILV

Stocks That Hit 52-Week Highs Of Monday

POWERSTORM HOLDINGS INC by Powerstorm Holdings, Inc.

Powerstorm Holdings Inc

Guidance

Management

Tech

ASML

ASML CEO Said AI-driven Shift Toward Advanced Logic And Memory Chips Benefits ASML

Rani Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.27) by 11.11 percent. This is a 33.33 percent increase over losses of $(0.36) per share from the same period last year.

Earnings

Earnings Beats

RANI

Rani Therapeutics Hldgs Q3 EPS $(0.24) Beats $(0.27) Estimate

IM Cannabis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCC#NASDAQ">IMCC</a>) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(1.41) by 70.92 percent.

IMCC

IM Cannabis Q3 2024 Adj EPS $(0.41) Beats $(1.41) Estimate

UBS analyst Michael Goldsmith downgrades Sun Communities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUI#NYSE">SUI</a>) from Buy to Neutral and lowers the price target from $155 to $134.

Downgrades

Price Target

Analyst Ratings

UBS Downgrades Sun Communities to Neutral, Lowers Price Target to $134

&nbsp;Enlivex Therapeutics Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENLV#NASDAQ">ENLV</a>, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced the completion of the dosing and initial follow-up period for the first patient in its Phase I clinical trial evaluating the safety, tolerability and potential therapeutic effect of Allocetra&#x2122; following injection into an affected joint in patients with psoriatic arthritis. No safety concerns were recorded following the dosing of the first patient.
The trial currently plans to recruit six patients who have insufficiently responded to conventional therapies for psoriatic arthritis. The primary safety endpoint will measure the frequency and severity of adverse events and serious adverse events, and secondary endpoints will include assessments of change from baseline in pain and other parameters of disease activity for up to 12 months following administration of Allocetra&#x2122;.

Biotech

General

ENLV

Enlivex Announces The Dosing Of The First Patient In A Phase I Clinical Trial  Evaluating The Safety, Tolerability And Potential Therapeutic Effect Of Allocetra In Patients With Psoriatic Arthritis

ASML CEO, AT Investor Day, Says Sees Global Chip Market Growing 9% Annually And Passing $1T In 2030; Sees AI Chips Making Up 40% Of Total Market In 2030 After Rapid Growth

Expands Arabic Content With New Series And Exclusive Concerts, Partners With UAE Telcos For 4K Streaming And Saudi Ministry Of Culture For Talent Development

AAPL

ANGH

Anghami Reports Strong 2024 Growth With 28% Increase In Video Streaming Engagement And 18% ARPU Rise; Launches AI-Driven Features, DolbyVision, And Apple Vision Pro App

Oppenheimer analyst Christopher Glynn maintains Applied Industrial Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIT#NYSE">AIT</a>) with a Outperform and raises the price target from $260 to $305.

Oppenheimer Maintains Outperform on Applied Industrial Techs, Raises Price Target to $305

JD.com,&nbsp;Inc.&nbsp;(NASDAQ:&nbsp;JD) reported fiscal second-quarter 2024 revenue growth of 5.1%&nbsp;year over year&nbsp;to $37.11 billion, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41964595/jd-com-announces-third-quarter-2024-results" rel="noreferrer noopener">analyst consensus estimate of $36.54 billion</a>.
JD posted&nbsp;an adjusted net income per ADS of $1.24, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate of $1.09</a>. The stock price slid after the print.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41943966/stratasys-ceo-touts-turnaround-strong-market-gains-cost-cuts-drive-q3-beat-guidance-raised" rel="noreferrer noopener">Stratasys CEO Touts Turnaround: Strong Market Gains, Cost Cuts Drive Q3 Beat, Guidance Raised</a>
JD Segment Performance: JD.com's&nbsp;net product revenue increased by 4.8%&nbsp;year over year&nbsp;at $29.16 billion. Net service revenues rose 6.5%&nbsp;year over year&nbsp;to $7.95 billion.&nbsp;
JD Retail revenue climbed 6.1%&nbsp;year over year&nbsp;to $32.06 billion, Logistics revenue gained 6.6% year over year to $6.33 billion, and the new business revenues fell to $708 million.
JD.com's marketing expenses rose 25.7% to $1.4 billion in the quarter, forming 3.8% of revenues. The rise was mainly due to the increased spending in promotion activities.
Margin: Operating margin was 4.6% for the quarter, compared to 3.8% year over year. Adjusted operating margin improved 50 bps year over year to 5.0%. JD Retail's operating margin remained stable year over year at 5.2%.&nbsp;
Adjusted EBITDA increased 17.0% year over year to $2.1 billion, with a 5.8% margin.
JD.com used $1.97 billion in free cash flow for the quarter, used $0.89 billion in operating cash flow, and held $28.0 billion in cash and equivalents as of September-end.
JD.com's CEO, Sandy Xu, highlighted strong topline growth and solid profitability in the third quarter, driven by improved consumer sentiment. Xu attributed the performance to JD.com's robust supply chain and fulfillment infrastructure, which played a key role in China's trade-in program. The company saw significant growth in the general merchandise category, fueled by efforts to enhance user experience and positive responses to the Singles Day Grand Promotion.
CFO Ian Su Shan noted that JD.com's revenues grew 5.1% year-over-year, supported by a rebound in electronics and home appliance sales alongside consistent strength in general merchandise. The company's focus on enhancing supply chain capabilities led to improved gross and non-GAAP net margins.
JD.Com stock gained over 31% year-to-date.
Price Action: JD stock is up 1.65% at $36.28 in the premarket session&nbsp;at the last check Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41940062/tower-semiconductor-q3-earnings-revenue-and-profit-beat-plans-350-million-expansion" target="_blank" rel="noreferrer noopener">Tower Semiconductor Q3 Earnings: Revenue And Profit Beat, Plans $350 Million Expansion</a></li>
</ul>
Photo via Wikimedia Commons

Emerging Markets

JD.com Q3 Earnings: Revenue Beats Forecast Amid Consumer Rebound, Highlights Supply Chain Strength, Eyes Margin Growth

Oppenheimer analyst Hartaj Singh maintains Astria Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXS#NASDAQ">ATXS</a>) with a Outperform and raises the price target from $26 to $28.

ATXS

Oppenheimer Maintains Outperform on Astria Therapeutics, Raises Price Target to $28

<a href="https://www.msn.com/en-us/money/markets/crude-oil-production-we-ve-reached-1-8m-barrels-per-day-nnpcl/ar-AA1u4xVK?ocid=finance-verthp-feeds" title="https://www.msn.com/en-us/money/markets/crude-oil-production-we-ve-reached-1-8m-barrels-per-day-nnpcl/ar-AA1u4xVK?ocid=finance-verthp-feeds">https://www.msn.com/en-us/money/markets/crude-oil-production-we-ve-reached-1-8m-barrels-per-day-nnpcl/ar-AA1u4xVK?ocid=finance-verthp-feeds</a>

Macro Economic Events

Commodities

Economics

Nigerian National Petroleum Company Limited Reaches 1.8M Barrels Per Day Of Oil Production

Sow Good (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOWG#NASDAQ">SOWG</a>) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.18) by 83.33 percent. This is a 925 percent decrease over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $3.55 million which missed the analyst consensus estimate of $5.47 million by 35.02 percent. This is a 29.40 percent decrease over sales of $5.03 million the same period last year.

Earnings Misses

SOWG

Sow Good Q3 EPS $(0.33) Misses $(0.18) Estimate, Sales $3.55M Miss $5.47M Estimate

Oppenheimer analyst Francois Brisebois maintains Tarsus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARS#NASDAQ">TARS</a>) with a Outperform and raises the price target from $63 to $65.

TARS

Oppenheimer Maintains Outperform on Tarsus Pharmaceuticals, Raises Price Target to $65

UBS analyst Christopher Schoell initiates coverage on Cogent Comms Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCOI#NASDAQ">CCOI</a>) with a Buy rating and announces Price Target of $102.

Initiation

CCOI

UBS Initiates Coverage On Cogent Comms Hldgs with Buy Rating, Announces Price Target of $102

Lexicon Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) today announced that data from four studies of sotagliflozin will be delivered during the American Heart Association's (AHA) Sessions 2024 being held November 16-18 at McCormick Place Convention Center in Chicago, Illinois.
One of those studies, a secondary analysis of data from the Phase 3 SCORED clinical trial, examined the association of heart failure stage with cardiovascular disease and kidney events. Researchers in the study observed that sotagliflozin had similar relative benefits for all endpoints, irrespective of heart failure stage, with a corresponding increase in absolute benefits at earlier stages.

LXRX

Lexicon Pharmaceuticals Reports Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum Of Heart Failure Patient Populations Is Among Four Presentations At The American Heart Association's Sessions 2024 in Chicago

WIIM

ONEW

OneWater Marine shares are trading lower after the company reported worse-than-expected Q4 financial results.

HC Wainwright &amp; Co. analyst Scott Buck maintains SoundHound AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) with a Buy and raises the price target from $7 to $8.

SOUN

HC Wainwright & Co. Maintains Buy on SoundHound AI, Raises Price Target to $8

Comments

Powerstorm Hldgs

Powerstorm Hldgs (PSTO) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga